Validity of the self-reported smoking status of schizophrenia patients, taking gender-related differences into consideration

被引:4
作者
Takeuchi, Takeaki [1 ,2 ]
Nakao, Mutsuhiro [1 ,2 ]
Shinozaki, Yasuko [1 ,3 ]
Yano, Eiji [1 ]
机构
[1] Teikyo Univ, Sch Med, Dept Hyg & Publ Hlth, Itabashi Ku, Tokyo 1738605, Japan
[2] Teikyo Univ Hosp, Div Psychosomat Med, Tokyo, Japan
[3] Kichijyoji Hosp, Div Psychiat, Tokyo, Japan
关键词
RECEPTOR PARTIAL AGONIST; CARBON-MONOXIDE; CESSATION; VARENICLINE; BUPROPION; COTININE; PLACEBO;
D O I
10.3109/13651501.2010.505342
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective. It is unclear whether self-reported smoking status reflects the true smoking status in schizophrenia patients. This study aims to evaluate the consistency in smoking status in schizophrenia patients, as determined using self-reported questionnaires and objective measurements, while considering gender-related differences. Methods. The study involved 158 Japanese schizophrenia patients (79 men and 79 women), who were diagnosed according to DSM-IV-TR criteria. The patients answered questions about their smoking status and daily cigarette consumption. The carbon monoxide (CO) level in the expired air was measured to confirm the self-reported answers. We descriptively analysed the data and assessed the proportion of results showing consistency between the self-reported smoking status and measured CO levels. Results. The self-reported smoking status was consistent with the objective measurement results in both genders. Among the various cut-off CO levels considered, 7 ppm was found to be the optimal level in both men and women. Conclusions. Our study showed that self-reporting is a reliable method for evaluating the smoking status of schizophrenia patients, regardless of gender. However, for precise assessment on the basis of CO levels in expired air, lower cut-off points may be better than the recommended ones.
引用
收藏
页码:282 / 286
页数:5
相关论文
共 15 条
[1]   Time response of cytochrome P450 1A2 activity on cessation of heavy smoking [J].
Faber, MS ;
Fuhr, U .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (02) :178-184
[2]   Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation -: A randomized controlled trial [J].
Gonzales, David ;
Rennard, Stephen I. ;
Nides, Mitchell ;
Oncken, Cheryl ;
Azoulay, Salomon ;
Billing, Clare B. ;
Watsky, Eric J. ;
Gong, Jason ;
Williams, Kathryn E. ;
Reeves, Karen R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (01) :47-55
[3]   Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease [J].
Hajiro, T ;
Nishimura, K ;
Tsukino, M ;
Ikeda, A ;
Koyama, H ;
Izumi, T .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (03) :785-790
[4]   Evaluating screening performances of the Fagerstrom tolerance questionnaire, the Fagerstrom test for nicotine dependence and the heavy smoking index among Taiwanese male smokers [J].
Huang, Chih-Ling ;
Lin, Hsi-Hui ;
Wang, Hsiu-Hung .
JOURNAL OF CLINICAL NURSING, 2008, 17 (07) :884-890
[5]   Comparison of expired carbon monoxide and plasma cotinine as markers of cigarette abstinence [J].
Jatlow, Peter ;
Toll, Benjamin A. ;
Leary, Vanessa ;
Krishnan-Sarin, Suchitra ;
O'Malley, Stephanie S. .
DRUG AND ALCOHOL DEPENDENCE, 2008, 98 (03) :203-209
[6]  
Kaplan H.I., 2007, Synopsis of Psychiatry
[7]   How should DSM-V criteria for schizophrenia include cognitive impairment? [J].
Keefe, Richard S. E. ;
Fenton, Wayne S. .
SCHIZOPHRENIA BULLETIN, 2007, 33 (04) :912-920
[8]  
Lawrence D., 2001, PREVENTABLE PHYS ILL
[9]  
Leung A, 2000, ACTA PSYCHIAT SCAND, V101, P3
[10]   Diet, smoking and cardiovascular risk in people with schizophrenia - Descriptive study [J].
McCreadie, RG .
BRITISH JOURNAL OF PSYCHIATRY, 2003, 183 :534-539